Ziltivekimab Stumbles in ZEUS: Novo Nordisk's Cardiovascular Outcomes Trial Misses Mark
NVO sits 36% above its 52-week low of $35.12.
Summary
Novo Nordisk's ZEUS phase 3 trial of ziltivekimab failed to meet its primary endpoint of reducing cardiovascular events in high-risk patients, a notable pipeline disappointment that will trigger a non-cash impairment charge in Q3 2026.
Key Events · Product Development and Regulatory · NVO
-
ZEUS Trial Misses Primary Endpoint
Ziltivekimab showed no reduction in MACE vs placebo (HR 0.99, 95% CI 0.88–1.11) in over 6,300 patients with ASCVD, CKD, and inflammation.
-
Non-Cash Impairment Charge Expected
Novo Nordisk will record a non-cash impairment charge in Q3 2026 related to the ZEUS failure, though the 2026 adjusted operating profit outlook is unchanged.
-
Two Other Ziltivekimab Trials Continue
The HERMES (heart failure) and ARTEMIS (post-heart attack) trials are ongoing, with readouts anticipated in the first half of 2027.
-
Safety Profile Consistent with IL-6 Inhibition
Serious infections were higher with ziltivekimab, consistent with its mechanism; overall adverse events were similar to placebo, with no difference in all-cause mortality.
Analysis · NVO · Life Sciences
In a significant setback for its cardiovascular pipeline, the ZEUS phase 3 trial—which enrolled over 6,300 patients with ASCVD, CKD, and inflammation—failed to show that ziltivekimab reduced major adverse cardiovascular events compared to placebo, yielding a hazard ratio of 0.99. While the 2026 profit outlook remains intact, the miss will trigger a non-cash impairment charge in Q3 2026. Two additional ziltivekimab studies, HERMES in heart failure and ARTEMIS in post-heart attack patients, are still underway, with data expected in the first half of 2027.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, NVO was trading at $47.64 on NYSE in the Life Sciences sector, with a market capitalization of approximately $225.6B. The 52-week trading range was $35.12 to $64.16. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.